Brief: Rocket Pharmaceuticals Provides Update On Phase 2 Clinical Trial Of Rp-A501 For Danon Disease
27/05/2025 13:10
May 27 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O: ROCKET PHARMACEUTICALS PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF RP-A501 FOR DANON DISEASE ROCKET PHARMACEUTICALS INC - IN ACTIVE DIALOGUE WITH FDA AFTER SAE IN RP-A501 TRIAL ROCKET PHARMACEUTICALS INC - FDA PLACES CLINICAL HOLD ON RP-A501 TRIAL AFTER SAE ROCKET PHARMACEUTICALS INC - PATIENT IN RP-A501 PHASE 2 TRIAL EXPERIENCES SERIOUS ADVERSE EVENT ROCKET PHARMACEUTICALS INC - EXPECTS RESOURCES TO FUND OPERATIONS INTO 2027 ROCKET PHARMACEUTICALS INC - UNABLE TO PROVIDE GUIDANCE ON ANTICIPATED TIMING FOR COMPLETION OF PHASE 2 TRIAL Source text: ID:nBwb5JtgFa Further company coverage: RCKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08